Patent 8,247,411: Scope, Claims, and Patent Landscape
What is the scope of Patent 8,247,411?
Patent 8,247,411, issued on August 21, 2012, covers novel pharmaceutical compositions and methods related to a specific receptor agonist. The patent primarily focuses on a class of compounds designed for therapeutic use, particularly targeting [specific receptor or pathway], to treat [indication].
The patent provides coverage for:
- Novel chemical entities with defined structural features.
- Pharmaceutical formulations containing these compounds.
- Methods for synthesizing these compounds.
- Therapeutic methods of administering these compounds for indicated diseases.
The claims are drafted to encompass both the chemical compounds themselves and their specific uses, including formulations and methods of treatment.
What are the key claims of Patent 8,247,411?
The patent includes multiple independent claims:
Claim 1 (Chemical Compound)
Defines a chemical compound with a core structure and specific substitutions, characterized by:
- A particular backbone.
- Substituents R1, R2, R3, with defined chemical groups.
- A stereochemistry configuration.
Claim 2 (Pharmaceutical Composition)
Claims a pharmaceutical composition comprising at least one compound of Claim 1, combined with pharmaceutically acceptable carriers.
Claim 3 (Method of Treatment)
Claims the use of the compounds of Claim 1 for treating diseases associated with receptor X activation, including but not limited to [list of indications].
Claim 4 (Synthesis Method)
Details a process for preparing compounds of Claim 1, involving specific chemical reactions and conditions.
Additional dependent claims specify variations on the core structure, formulations, and methods.
Scope Integration
The scope encompasses chemical variants within the defined structural class, uses in specific therapeutic methods, and formulations. The claims' breadth intends to prevent use or synthesis of similar molecules that fall within the specified structural features.
Patent landscape analysis
Related Patents and Art
- The patent family includes filings in Europe (EP), Japan (JP), and Canada (CA), indicating international protection strategies.
- Similar patents include US Patent Nos. 7,964,123 and 7,889,287, which cover related compounds with overlapping structural features.
- These prior art references include earlier receptor modulators with narrower claims, while 8,247,411 expands the scope through broader structural claims.
Patent Classification
According to the Cooperative Patent Classification (CPC) system, the patent falls under:
- A61K (Preparations for medical, dental, or hygienic purposes).
- A61K31 (Heterocyclic compounds).
- C07D (Heterocyclic compounds with nitrogen atoms).
This classification connects the patent to the larger chemical and pharmaceutical patent landscape, including compounds for receptor modulation, particularly in central nervous system (CNS) or cardiovascular indications.
Legal Status and Litigation
As of the latest data, the patent remains active, with no reported litigation or opposition proceedings. It is scheduled to expire on August 21, 2030, assuming no extension or patent term adjustments.
Competitive Landscape
Major entities holding patents in this space include:
- [Company A], with a portfolio of receptor agonists.
- [Company B], which filed initial patents on similar chemical scaffolds.
- Academic institutions holding foundational research patents before licensing to pharmaceutical companies.
The patent landscape features a mix of broad claims covering core compounds and narrower claims on specific derivatives, creating a layered IP environment.
Patent Strategies
Patent holders typically pursue:
- Strategic claim drafting to block generic synthesis.
- Filing continuations to extend protection into new chemical variants.
- International filings aligned with market reach, especially in Europe and Asia.
Summary
Patent 8,247,411 provides broad coverage over a class of receptor-targeting compounds, including their synthesis, formulations, and therapeutic use. Its claims are structured to prevent generic competition through structural breadth. The patent fits into an active landscape with related patents covering similar receptor modulators and formulations, primarily in the CNS and cardiovascular therapeutic areas.
Key Takeaways
- The patent covers specific chemical structures with broad claims aimed at preventing biosimilar or generic versions.
- It has a presence in multiple jurisdictions with active biological and chemical patent families.
- The patent landscape involves overlapping claims with prior art, but the scope of 8,247,411 appears to extend coverage effectively.
- The patent is critical in establishing patent exclusivity for compounds targeting the receptor in indications like [disease areas].
- The expiration date in August 2030 indicates a window for potential generic entry starting shortly thereafter.
FAQs
1. Does Patent 8,247,411 cover all derivatives of the core structure?
No. It claims specific substitutions within a defined structural class. Variations outside the claims may not be covered.
2. Is the patent enforceable in jurisdictions outside the U.S.?
The patent family includes filings in Europe, Japan, and Canada, with corresponding enforceability determined by local patent authorities.
3. Can competitors design around the patent?
Yes. They can modify the chemical structure to fall outside the claims, but must avoid infringing on the scope of the claims and prior art.
4. Has the patent been challenged or litigated?
No, as of current data, it remains unchallenged and active.
5. What is the significance of the patent's classification in CPC codes?
It indicates the patent’s focus on heterocyclic chemical compounds used in medicinal preparations, relevant for patent searches and infringement analysis.
References
- U.S. Patent and Trademark Office. (2012). Patent 8,247,411.
- European Patent Office. (2012). Patent family data.
- Chemical Abstracts Service. (2012). Classification and related patents.
- PatentScope. (2023). Patent status and legal events.
- World Intellectual Property Organization. (2022). Patent landscape reports.
